Literature DB >> 12767483

Unaltered pain-related behavior in mice lacking NMDA receptor GluRepsilon 1 subunit.

Andrei B Petrenko1, Tomohiro Yamakura, Hiroshi Baba, Kenji Sakimura.   

Abstract

Noxious afferent input following tissue damage and inflammation triggers a state of neuronal hyperexcitability-a phenomenon of central sensitization-which manifests behaviorally as allodynia and hyperalgesia. At the molecular level, maintenance of central sensitization is largely dependent on the N-methyl-D-aspartate receptor (NMDAR) activation. NMDARs are composed of GluRzeta1 (NR1) and one of four GluRepsilon (NR2) subunits, which determine the functional properties of native NMDARs. Although there is accumulating evidence to implicate GluRepsilon 2-containing NMDARs in pain mechanisms, the functional significance of GluRepsilon 1-containing NMDARs in this setting has not been examined in detail. Here, we used hind paw injection of formalin, complete Freund's adjuvant and a nerve injury model to investigate the effects of GluRepsilon 1 subunit gene deletion on pain-related behavior in mice. In all of the models tested, GluRepsilon 1-deficient mice exhibited responses similar to wild-type controls. These results suggest that GluRepsilon 1 disruption does not result in altered nociceptive behavior in mice. Although the contribution of other nociceptive pathways cannot be ruled out, we speculate that the preserved function of GluRepsilon 2-containing NMDARs could explain unaltered nociceptive behavior in mutant mice.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12767483     DOI: 10.1016/s0168-0102(03)00061-0

Source DB:  PubMed          Journal:  Neurosci Res        ISSN: 0168-0102            Impact factor:   3.304


  6 in total

Review 1.  Ionotropic glutamate receptors in spinal nociceptive processing.

Authors:  Max Larsson
Journal:  Mol Neurobiol       Date:  2009-10-31       Impact factor: 5.590

2.  Opioid antinociception, tolerance and dependence: interactions with the N-methyl-D-aspartate system in mice.

Authors:  Linda A Dykstra; Bradford D Fischer; Rebecca E Balter; Fredrick E Henry; Karl T Schmidt; Laurence L Miller
Journal:  Behav Pharmacol       Date:  2011-09       Impact factor: 2.293

Review 3.  Targeting the NMDA receptor subunit NR2B for the treatment of neuropathic pain.

Authors:  Long-Jun Wu; Min Zhuo
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

4.  Effects of Shugan Hewei Granule on Depressive Behavior and Protein Expression Related to Visceral Sensitivity in a Rat Model of Nonerosive Reflux Disease.

Authors:  Yi Wang; Guanwu Li; Xiaosu Wang; Shengliang Zhu
Journal:  Evid Based Complement Alternat Med       Date:  2019-01-02       Impact factor: 2.629

5.  Complement Receptor 3 Pathway and NMDA Receptor 2B Subunit Involve Neuropathic Pain Associated with Spinal Cord Injury.

Authors:  Yong Li; Sheng-Chun Fang; Lan Zhou; Xue-Mei Mo; Hao-Dong Guo; Yan-Bo Deng; Hong-Hao Yu; Wei-Yi Gong
Journal:  J Pain Res       Date:  2022-06-25       Impact factor: 2.832

6.  Functional identification of NR2 subunits contributing to NMDA receptors on substance P receptor-expressing dorsal horn neurons.

Authors:  Chi-Kun Tong; Edward J Kaftan; Amy B Macdermott
Journal:  Mol Pain       Date:  2008-10-10       Impact factor: 3.395

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.